Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 354

1.

Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ.

J Clin Oncol. 2010 Nov 1;28(31):4730-9. doi: 10.1200/JCO.2009.27.7665.

PMID:
20855822
2.

Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.

Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R.

Blood. 1998 Aug 15;92(4):1150-9.

3.

Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT.

Arch Dermatol. 2003 Jul;139(7):857-66.

PMID:
12873880
4.

Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.

Fraser-Andrews EA, Mitchell T, Ferreira S, Seed PT, Russell-Jones R, Calonje E, Whittaker SJ.

Br J Dermatol. 2006 Oct;155(4):756-62.

PMID:
16965425
5.

Prognostic factor analysis in mycosis fungoides/Sézary syndrome.

Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R.

J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24.

PMID:
10365922
6.

A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.

Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, Mitchell TJ, Cox M, Ferreira S, Liu P, Robson A, Calonje E, Stefanato CM, Wilkins B, Scarisbrick J, Wain EM, Child F, Morris S, Duvic M, Whittaker SJ.

Eur J Cancer. 2013 Sep;49(13):2859-68. doi: 10.1016/j.ejca.2013.04.018.

PMID:
23735705
7.

Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas.

Grange F, Hedelin G, Joly P, Beylot-Barry M, D'Incan M, Delaunay M, Vaillant L, Avril MF, Bosq J, Wechsler J, Dalac S, Grosieux C, Franck N, Esteve E, Michel C, Bodemer C, Vergier B, Laroche L, Bagot M.

Blood. 1999 Jun 1;93(11):3637-42.

8.

Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.

Alberti-Violetti S, Talpur R, Schlichte M, Sui D, Duvic M.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e105-12. doi: 10.1016/j.clml.2015.02.027.

PMID:
25817937
9.

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH.

J Clin Oncol. 2015 Nov 10;33(32):3766-73. doi: 10.1200/JCO.2015.61.7142.

10.

Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.

Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, Glatstein E, Ihde DC, Kaye F, Veach SR, et al.

Ann Intern Med. 1988 Sep 1;109(5):372-82.

PMID:
3408055
11.
13.

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, Whittaker S; ISCL/EORTC..

Blood. 2007 Sep 15;110(6):1713-22. Review. Erratum in: Blood. 2008 May 1;111(9):4830.

14.

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.

Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.

J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. Review.

PMID:
24438970
15.

Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.

Suzuki SY, Ito K, Ito M, Kawai K.

J Dermatol Sci. 2010 Jan;57(1):37-43. doi: 10.1016/j.jdermsci.2009.10.010.

PMID:
19931424
16.

Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.

Tobisawa S, Honma M, Ishida-Yamamoto A, Saijo Y, Iizuka H.

J Dermatol Sci. 2013 Sep;71(3):160-6. doi: 10.1016/j.jdermsci.2013.04.020.

PMID:
23702390
17.

Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.

Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, Wei W, Duvic M.

Clin Cancer Res. 2012 Sep 15;18(18):5051-60. doi: 10.1158/1078-0432.CCR-12-0604.

18.

Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL, Olavarría E, Schmitz N, Sureda A.

J Clin Oncol. 2010 Oct 10;28(29):4492-9. doi: 10.1200/JCO.2010.29.3241.

PMID:
20697072
19.

Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.

Vidulich KA, Talpur R, Bassett RL, Duvic M.

Int J Dermatol. 2009 Mar;48(3):243-52. doi: 10.1111/j.1365-4632.2009.03771.x.

PMID:
19261011
20.

Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.

Kim YH, Bishop K, Varghese A, Hoppe RT.

Arch Dermatol. 1995 Sep;131(9):1003-8.

PMID:
7661601
Items per page

Supplemental Content

Support Center